HEALTH● LOWAug 30 · Aug 30, 2026, 7:01 PM
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss
Seeking Alpha Tech · global
Tenax has identified a benefit in a sicker patient subgroup, despite missing its primary endpoint in a Phase 3 trial. This finding could indicate specific efficacy for a targeted patient population.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH2h agoEdwards Lifesciences says PASCAL beats medical therapy for tricuspid repairSeeking Alpha TechHEALTH2h agoFitness program cut transplant waitlist death risk by half, study findsThe HillHEALTH3h agoUS dairy worker dies from bird flu as outbreak rages in cattleThe TelegraphHEALTH3h agoHealth Review: Ebola case, child malnutrition, medicine security, other developments that shaped OctoberPremium Times